Sultolin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sultolin

Property Description
Active ingredient Salbutamol (Albuterol)
Form Inhaler (MDI), Solution for Nebulization
Pharmacological class Selective beta-2 adrenergic receptor agonist
General purpose Rapid relief of acute airway constriction
Origin Synthetic

Sultolin's Classification and Active Ingredient

Sultolin is a brand name for a prescription medicine whose sole active substance is Salbutamol, which is recognized as Albuterol in the United States. It is formally classified as a selective beta-2 adrenergic receptor agonist, belonging to the functional category of short-acting beta-agonists (SABA). This pharmacological type is clinically recognized for its capacity to address sudden breathing difficulty. Salbutamol is recognized as a core medicine.

Composition, Forms, and Differentiation

The core composition of Sultolin is the single-active ingredient Salbutamol, often supplied as its sulfate salt, synthesized chemically rather than derived from a natural source. Sultolin is primarily designed for inhalation, available most commonly as a metered-dose inhaler (MDI) or as an aqueous solution for nebulization. The mechanism of Salbutamol's action promotes the relaxation of airway smooth muscles. This action means the medicine helps to quickly open the constricted air passages.

General Therapeutic Purpose

The fundamental purpose of Sultolin is to provide rapid relief during acute episodes of constricted breathing. The drug functions by achieving smooth muscle relaxation in the air passages through the stimulation of beta-2 receptors, effectively reversing bronchospasm, the sudden tightening of the airways. Functioning as an essential rescue inhaler agent, Sultolin’s core benefit is the capacity to immediately and effectively restore adequate airflow, which is critical during immediate breathing difficulties.

Regulatory References

  1. World Health Organization’s Model List of Essential Medicines
  2. MedlinePlus Drug Information

What side effects are possible with Sultolin?

Adverse Reactions and Safety Profile

Sultolin (albuterol/salbutamol), a selective beta2-adrenergic agonist, is associated with a range of side effects stemming from its sympathomimetic activity. The most commonly reported adverse reactions include fine tremor (particularly of the hands), headache, nervousness, and tachycardia (increased heart rate) or palpitations. Other common effects include dizziness, throat irritation, and cough.

Serious and Clinically Significant Risks

Official regulatory labeling highlights several serious adverse reactions that require immediate attention:

  • Paradoxical Bronchospasm: As with other inhaled beta2-agonists, this drug can cause a life-threatening, sudden worsening of wheezing or breathing difficulty immediately after use. If this occurs, the product must be discontinued and alternative therapy initiated.
  • Cardiovascular Effects: Clinically significant changes in pulse rate, blood pressure, and/or heart rhythm (including arrhythmias like atrial fibrillation) have been reported. Excessive use may be fatal.
  • Hypokalemia: Significant, though typically transient, decreases in serum potassium levels may occur, which can potentially lead to adverse cardiovascular effects.
  • Immediate Hypersensitivity Reactions: Rare cases of severe allergic reactions, including anaphylaxis, angioedema, urticaria, and rash, have been reported post-marketing, requiring immediate discontinuation.

Safety Restrictions and Monitoring

Sultolin is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. Caution is advised when used in patients with underlying cardiovascular disorders (e.g., coronary insufficiency, hypertension), convulsive disorders, diabetes mellitus, or hyperthyroidism, as the drug may exacerbate these conditions. Use with non-selective beta-blockers is generally avoided as it may block the bronchodilatory effect and produce severe bronchospasm. Patients must be warned not to exceed the prescribed dose and should seek medical evaluation if their asthma control deteriorates (e.g., increasing need for the medication).

Overdose and Emergency Response

Overdose involving Sultolin (salbutamol/albuterol) results from an exaggeration of its known pharmacological effects, according to regulatory documentation. Documented manifestations include severe cardiovascular, neurological, and metabolic disturbances.

Documented Overdose Manifestations

System Clinical and Physiological Findings
Cardiovascular Tachycardia, palpitations, and potentially severe tachyarrhythmias, myocardial ischemia, or cardiac arrest.
Metabolic Severe hypokalemia (low serum potassium), hyperglycemia, and metabolic acidosis (lactic acidosis).
Neurological Tremor, nervousness, headache, and uncontrollable shaking.

Exceeding the approved dosage can be fatal. Consequently, official government labeling mandates that patients seek immediate medical attention for any suspected overdose or accidental ingestion, even if symptoms are not yet present. Contacting a Poison Control Center or emergency services immediately is required.

Management in an overdose situation is primarily supportive. Regulatory documents state that continuous ECG monitoring and careful observation of serum potassium levels are necessary due to the risk of cardiac and electrolyte abnormalities. While no specific antidote is known, cardioselective beta-blocking agents may be considered under strict medical supervision, but only with extreme caution due to the risk of inducing severe bronchospasm.

Therapeutic Uses of Sultolin

What Sultolin Treats: Main Uses and Benefits

Sultolin (salbutamol/albuterol) is a prescription medication primarily used as a bronchodilator to address acute symptoms related to reversible obstructive airway disease. Its main purpose is to help relieve the sudden tightening of muscles in the airways, known as bronchospasm.

This medication is used to manage symptoms associated with lung conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. These symptoms may include difficulty breathing, wheezing, shortness of breath, coughing, and chest tightness. Sultolin is also indicated for the prevention of exercise-induced bronchospasm, a scenario where it is used proactively before physical exertion. The benefit of this medication is its ability to provide quick relief and promptly address symptoms, which may help to ease breathing.

“A primary function of salbutamol is its role as a 'reliever' for the management of acute breathing difficulties.”

Symptom Focus: Shortness of Breath

The conditions Sultolin helps manage are asthma, chronic bronchitis, emphysema, and exercise-induced bronchospasm.

Eligibility and Restrictions for Use

Sultolin eligibility is governed by official regulatory standards that define who is approved for use and who is strictly prohibited.

Contraindicated Populations

Use of this medicine is contraindicated for any individual with a history of hypersensitivity or severe allergic reaction to Salbutamol (Albuterol) or to any of the specific product’s excipients. Non-intravenous formulations are also contraindicated for managing uncomplicated premature labor or threatened abortion.

Age-Related Eligibility Rules

Eligibility is established for adults and adolescents. For metered-dose inhaler (MDI) formulations, use is established for children aged four years and older. Safety and effectiveness in children younger than four years is generally not established by regulatory bodies.

Condition-Specific Eligibility

Sultolin must be used with caution in patients who have certain pre-existing comorbidities. These include cardiovascular disorders such as hypertension and cardiac arrhythmias, as well as metabolic conditions like diabetes mellitus and hyperthyroidism.

Pregnancy and Lactation Status

For both pregnancy and lactation, official regulatory documentation advises that use should only be considered if the potential benefit to the patient justifies any possible risk.

What should I know about interactions with other medicines?

The official regulatory profile for Sultolin (salbutamol/albuterol) documents specific drug-drug interactions, primarily classified by their effect on the body's systems or the drug's exposure.

Co-administration with other short-acting sympathomimetic aerosol bronchodilators is not recommended due to the potential for deleterious cardiovascular effects. The use of non-cardioselective Beta-Adrenergic Receptor Blocking Agents is generally advised against in patients with asthma because these agents may block Sultolin’s pulmonary effects and risk precipitating severe bronchospasm.

Regulatory documents define several potentiation risks. Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate Sultolin's effects on the vascular system. Consequently, Sultolin should be used with extreme caution if MAOIs or TCAs have been discontinued within the preceding two weeks.

A pharmacokinetic interaction is documented with Digoxin, where co-administration has been shown to cause a mean decrease in its serum levels. Furthermore, the combination of Sultolin with Non-Potassium-Sparing Diuretics, Corticosteroids, or Xanthine Derivatives may acutely worsen or potentiate the risk of hypokalemia (low potassium). Caution is also advised when Sultolin is used alongside certain Halogenated Anaesthetics due to the documented risk of serious ventricular rhythm disorders.

Mechanism of Action

Selective Activation of Beta-2 Receptors

Sultolin's action begins by selectively engaging the beta-2 adrenergic receptors (beta2-AR) found on the surface of airway smooth muscle cells, acting as a selective agonist. This targeted molecular interaction immediately triggers a signal transduction cascade that results in bronchial smooth muscle relaxation.


Intracellular Signal Transduction and Muscle Relaxation

Binding to the beta2-AR activates the Gs-protein/cAMP signaling pathway inside the cell . This mechanism rapidly increases intracellular cAMP levels, which leads to the phosphorylation and inhibition of key enzymes like Myosin Light-Chain Kinase (MLCK). Concurrently, it facilitates the reduction of free calcium ions ( Ca^2+) in the cytoplasm. The resulting biochemical change directly controls the muscle's ability to contract, leading to bronchodilation.


Mechanistic Limitations

The mechanism's repeated or prolonged engagement can lead to receptor desensitization and down-regulation (tachyphylaxis). This constraint means the continuous stimulation of the beta2-AR can cause the smooth muscle to exhibit a reduced physiological response over time.

Dosage and Administration Information

How to Use Sultolin

The usage of Sultolin (salbutamol/albuterol) involves specific administration routes, standardized dosages, and established schedules.


Official Administration and Dosing

Sultolin is primarily administered via oral inhalation using a metered-dose inhaler (MDI) or as a solution for nebulization. Oral forms, such as tablets and syrup, are also available for use. The standard dose for acute symptom relief using the MDI is 2 inhalations (180 mcg albuterol base), which may be repeated every 4 to 6 hours as required. Administration generally does not exceed a total of 8 inhalations in a 24-hour period.

For prophylaxis against exercise-induced symptoms, the standard dose of 2 inhalations is taken specifically 15 to 30 minutes prior to the start of physical activity. When using nebulization, the typical dose is 2.5 mg of albuterol base, with repetition permitted up to four times daily in routine settings.


Procedural Requirements and Adjustments

Proper administration requires attention to device preparation. A new MDI device, or one that has not been used for over two weeks, is primed (e.g., using four test sprays) before use to ensure accurate dose delivery. Furthermore, the inhaler actuator is typically cleaned with warm water and air-dried at least once weekly. Concentrated nebulization solutions (e.g., 0.5%) require dilution with sterile normal saline to the necessary volume before administration.

Population-specific adjustments are established in clinical guidance; for instance, the initial oral dosing for older adults may be restricted to a lower starting amount, such as 2 mg three or four times per day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sultolin

The available research for Sultolin (salbutamol/albuterol) focuses on its intended use in situations requiring short-term intervention for breathing difficulties. The evidence base, reviewed by governmental regulators and scientific bodies, is primarily composed of Randomized Controlled Trials (RCTs), systematic reviews, and specialized studies that examine the medicine's profile over a short timeframe. Research explores how this medicine was evaluated in patients experiencing specific conditions where symptoms may vary in intensity.


Evidence for Rapid Relief of Acute Breathing Difficulties

The most extensive body of evidence for Sultolin research examined its role in addressing the sudden tightening of airways, known as bronchospasm, which is commonly associated with asthma and COPD (Chronic Obstructive Pulmonary Disease).

Outcomes Measured in Acute Relief Studies

Research examined how outcomes related to functional status changed over defined time intervals. Studies monitored changes in objective lung function, such as the Forced Expiratory Volume in 1 second ( FEV1), to assess airway opening. Furthermore, trials investigated the time needed for changes in measured outcomes to be observed and documented the duration over which the observed changes in airway function measurements were maintained. Findings describe patterns observed in the studies related to patient-reported outcomes describing perceived discomfort, such as wheezing and chest tightness.

A key limitation noted in the research is that the results apply only to the populations studied and that the follow-up durations were limited to primarily capturing the initial and immediate short-term changes. The evidence base clarifies that the research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.


Research Gaps and Areas of Uncertainty

This medicine was observed in research that provided context but not individual predictions. The evidence base highlights what is known and what is still uncertain across regulatory and scientific reviews:

  • Evidence is limited regarding the long-term impact on the underlying course of chronic conditions like persistent asthma or COPD.
  • Data for certain groups remain insufficient, particularly for patients with multiple complex health issues or rare forms of airway disease.
  • The observed changes in outcomes of the medication may be linked to the inhaler technique, which is a factor that introduces variability outside of controlled studies.
  • Comparative evidence for how this medication performs against other similar short-term interventions in real-world observational settings is often less consistent than the foundational RCT data.

Key Studies & References

  1. MedlinePlus Drug Information: Albuterol Oral Inhalation

Frequently Asked Questions (FAQ)

Common questions about Sultolin (FAQ)


Q: What is the difference between Sultolin and a Ventolin inhaler?

A: Sultolin (Albuterol) and Ventolin are essentially the same medication. Salbutamol, known as Albuterol in the United States, is the active ingredient in both. Ventolin is simply one of the brand names used for the Salbutamol drug.


Q: Does Sultolin help with all types of breathing difficulties?

A: Official information indicates this medicine is specifically designed for the relief and prevention of bronchospasm, which is the sudden tightening of the airways. It is used in conditions like asthma and COPD (Chronic Obstructive Pulmonary Disease). It is not indicated for treating all underlying causes of breathing difficulties.


Q: Will taking Sultolin make me feel tired or drowsy?

A: Official safety data lists somnolence (drowsiness) or sleepiness as documented adverse effects, although they are generally considered less common than side effects like tremor or nervousness. If you notice unusual fatigue, it may be helpful to consult with a healthcare professional.


Q: Is Sultolin safe to use during pregnancy or while breastfeeding?

A: According to regulatory documents, use during pregnancy or while breastfeeding should only be considered if the expected benefit to the patient is greater than any potential risk to the fetus or infant. Salbutamol, the active ingredient, is known to likely be secreted into breast milk.


Q: Why do some people say they have a bad taste in their mouth after using Sultolin?

A: Regulatory safety information confirms that a change in taste, described as an unpleasant or unusual taste, is a commonly reported adverse reaction. This is generally linked to the way the inhaled medication is administered.


Q: What happens if I accidentally use Sultolin too close to my last dose?

A: Official reports of use exceeding the recommended amount describe features consistent with overdosage. These features may include effects expected from stimulating the body's nervous system, such as a rapid heart rate (tachycardia), increased tremor, and changes in blood chemistry, such as low potassium (hypokalemia).


Q: Can people with diabetes safely use Sultolin?

A: Regulatory warnings advise that Sultolin should be used with caution in patients who have diabetes mellitus. While the medication can sometimes lead to an increase in blood sugar, this change is typically transient. Monitoring of blood sugar levels may be necessary, as determined by a healthcare provider.


Q: Will Sultolin affect my ability to drive or operate machinery?

A: The official product safety information lists side effects such as dizziness, nervousness, and tremor (shakiness). The presence of these effects suggests that caution regarding driving or operating heavy machinery may be warranted until the medicine's effects are known.


Q: Is it possible for Sultolin to cause a headache?

A: Yes, regulatory safety data lists headache as a commonly reported adverse reaction associated with the use of this medication.


Q: What is the difference between the inhaler and the nebulizer solution of Sultolin?

A: Both the inhaler and the nebulizer solution contain the same active ingredient, Salbutamol/Albuterol, but they are different forms of delivery. The inhaler is an aerosol spray, while the nebulizer uses an aqueous solution. They also have different officially approved doses and delivery methods for administration.


Q: Does Sultolin lose its effectiveness over time with repeated use?

A: The physiological mechanism of this type of medicine can lead to 'receptor desensitization' over time, which means the smooth muscles may exhibit a reduced response to continuous stimulation. Literature referenced in official information has suggested that frequent or continuous use may be associated with a deterioration in asthma control.


Q: What happens to the Sultolin in my body after it has worked?

A: According to official pharmacokinetic data, the active ingredient Albuterol is primarily broken down in the liver by an enzyme called sulfotransferase (SULT1A3). The medication is then eliminated from the body with a half-life of approximately six hours.


Q: What should I do if my Sultolin inhaler freezes in cold weather?

A: Official handling instructions state that the device should not be refrigerated or frozen, as this can damage the medicine or the device. If the device fails to provide relief after temperature exposure, professional evaluation or replacement may be necessary.


Q: How do I know if the Sultolin canister is almost empty?

A: Many modern Sultolin inhaler devices feature a dose counter window that shows the number of sprays remaining in the canister. Replacement of the inhaler is necessary when the dose counter reaches zero.


Q: Is the effect of Sultolin stronger if I hold my breath after inhaling?

A: The official instructions for use often include the direction to hold your breath for a period of time—typically up to ten seconds—after inhaling the medicine. Following administration steps, including the recommended breath-hold, is part of ensuring proper delivery.


Q: Can Sultolin cause problems with sleep or insomnia?

A: Official safety profiles list sleep disturbance as an uncommon adverse effect and insomnia (difficulty sleeping) as a very rare effect. These effects are related to the medication's stimulating properties on the central nervous system.


Q: What's the best way to clean and maintain the Sultolin inhaler device?

A: Official instructions for the inhaler device typically recommend cleaning the actuator (the plastic piece that holds the canister) at least once per week. This usually involves removing the metal canister and rinsing the actuator under warm, running water for 30 seconds, followed by visual inspection and thorough air-drying.


Q: Why do people with allergies sometimes use Sultolin?

A: Salbutamol is used to treat bronchospasm (airway tightening). Because bronchospasm is a common symptom in allergic asthma—where allergens trigger the airway reaction—people with allergies may be prescribed this medication to relieve those specific breathing symptoms.


Q: Can I travel internationally with my Sultolin inhaler?

A: Authoritative travel security agencies generally permit medically necessary aerosol medications in reasonable quantities for travel. It is recommended, but not strictly required, that the medication be properly labeled for airport inspection.


Q: Is a slightly metallic taste after using Sultolin normal?

A: Yes, regulatory safety information confirms that a change in taste, which includes a bad or unusual taste, is a reported adverse reaction when using this inhaled medication.


Q: Does using Sultolin help prevent future breathing attacks?

A: Sultolin is officially indicated for the immediate relief and treatment of existing bronchospasm. It is also used prophylactically (preventatively) for exercise-induced bronchoconstriction, meaning it can prevent breathing difficulties specifically triggered by exercise when taken shortly beforehand.


Q: Can Sultolin affect the results of an EKG or other heart tests?

A: Due to its stimulating nature, Salbutamol is known to cause clinically significant changes in pulse rate, blood pressure, and heart rhythm. Published studies have observed changes in heart rate variability, which could potentially be seen on heart tests like an EKG.


Q: Is it normal for my throat to feel irritated after inhaling Sultolin?

A: Yes, mouth and throat irritation is listed in the official safety profile as a commonly reported adverse reaction associated with the use of the inhaler.

How should Sultolin be stored and disposed of?

Official Storage and Disposal Instructions

Storage of the Sultolin (albuterol sulfate) inhaler must adhere to strict regulatory requirements to ensure product integrity and safety.

Requirement Type Official Instructions
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not expose the canister to temperatures above 50 C (120 F).
Prohibited Do not refrigerate or freeze. Protect from excessive heat and direct sunlight. The pressurized canister must not be punctured, broken, or burned.
Stability The inhaler must be discarded either by the expiration date or after a specific in-use period (e.g., 3 or 13 months) following removal from the foil pouch, whichever comes first.
Protection Store the inhaler out of the reach of children.
Disposal The unused or expired canister must not be thrown into household trash or wastewater. Disposal should follow local regulations, often requiring return to a pharmacy or drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sultolin found in:

A-Z Index: